Related Experiment Video
Updated: Sep 20, 2025
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
From Therapy Resistance to Targeted Therapies in Prostate Cancer
Filipa Moreira-Silva1, Rui Henrique1,2,3, Carmen Jerónimo1,3
1Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (He-alth Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC), Porto, Portugal.
Abstract:
Prostate cancer (PCa) is the second most common malignancy among men worldwide. Although early-stage disease is curable, advanced stage PCa is mostly incurable and eventually becomes resistant to standard therapeutic options. Different genetic and epigenetic alterations are associated with the development of therapy resistant PCa, with specific players being particularly involved in this process. Therefore, identification and targeting of these molecules with selective inhibitors might result in anti-tumoral effects. Herein, we describe the mechanisms underlying therapy resistance in PCa, focusing on the most relevant molecules, aiming to enlighten the current state of targeted therapies in PCa. We suggest that selective drug targeting, either alone or in combination with standard treatment options, might improve therapeutic sensitivity of resistant PCa. Moreover, an individualized analysis of tumor biology in each PCa patient might improve treatment selection and therapeutic response, enabling better disease management.
Insights
Prostate cancer (PCa) resistance to therapy is driven by genetic changes. Targeting specific molecules may improve treatment sensitivity for advanced PCa.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer (PCa) is a leading global malignancy in men.
- Early-stage PCa is curable, but advanced stages often become resistant to treatments.
- Genetic and epigenetic alterations drive therapy resistance in PCa.
Purpose of the Study:
- To elucidate the mechanisms of therapy resistance in prostate cancer.
- To identify key molecular players involved in treatment resistance.
- To review the current landscape of targeted therapies for PCa.
Main Methods:
- Review of scientific literature on PCa therapy resistance mechanisms.
- Analysis of genetic and epigenetic alterations in resistant PCa.
- Evaluation of targeted therapeutic strategies and molecular inhibitors.
Main Results:
- Specific molecular alterations significantly contribute to PCa therapy resistance.
- Targeting these molecules with selective inhibitors shows potential anti-tumoral effects.
- Combination therapies and individualized treatment approaches may enhance efficacy.
Conclusions:
- Understanding PCa resistance mechanisms is crucial for developing effective treatments.
- Selective drug targeting offers a promising strategy to overcome therapy resistance.
- Personalized medicine based on tumor biology can optimize treatment selection and patient outcomes.
More Related Videos
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy